These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 8261429

  • 1. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T.
    Cancer Res; 1994 Jan 01; 54(1):109-13. PubMed ID: 8261429
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
    Schleyer E, Braess J, Ramsauer B, Unterhalt M, Kaufmann C, Wilde S, Schüssler M, Hiddemann W.
    Leukemia; 1995 Jun 01; 9(6):1085-90. PubMed ID: 7596174
    [Abstract] [Full Text] [Related]

  • 3. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
    Nishikawa M, Morita K, Komada F, Uemura Y, Kageyama S, Minami N, Deguchi K, Shirakawa S.
    Gan No Rinsho; 1990 Oct 01; 36(12):2204-9. PubMed ID: 2232191
    [Abstract] [Full Text] [Related]

  • 4. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 5. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE, Plunkett W, Linker CA.
    Cancer Res; 1991 Aug 15; 51(16):4141-5. PubMed ID: 1868435
    [Abstract] [Full Text] [Related]

  • 6. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 7. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 15; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T.
    Anticancer Res; 2003 Nov 15; 23(6D):5037-42. PubMed ID: 14981964
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [A new antileukemic drug, cytarabine ocfosfate].
    Tsukagoshi S.
    Gan To Kagaku Ryoho; 1993 Sep 15; 20(12):1877-83. PubMed ID: 8379682
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
    Ueda T, Nakamura T, Kagawa D, Uchida M, Domae N, Sugiyama M, Ueda Y, Sasada M, Uchino H.
    Cancer Chemother Pharmacol; 1989 Sep 15; 24(6):371-5. PubMed ID: 2791191
    [Abstract] [Full Text] [Related]

  • 12. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 13. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
    Ueda Y, Mori S, Ito T, Maesako Y, Konishi H, Yagiri Y.
    Rinsho Ketsueki; 1998 May 15; 39(5):348-54. PubMed ID: 9637884
    [Abstract] [Full Text] [Related]

  • 14. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R.
    Cancer Res; 1989 Jan 01; 49(1):241-7. PubMed ID: 2908850
    [Abstract] [Full Text] [Related]

  • 15. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T, Shibasaki C, Ishii T, Uchida T, Arakawa M, Kusama K, Ekimoto H, Takahashi K.
    Gan To Kagaku Ryoho; 1990 Aug 01; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [Abstract] [Full Text] [Related]

  • 16. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
    Fukuoka M, Miyazaki T, Yoshida Y, Hattori M, Niitani H, Nakamura T, Hirota Y, Ohta K, Tanaka M, Suzuoki Y.
    Gan To Kagaku Ryoho; 1990 Nov 01; 17(11):2213-9. PubMed ID: 2241185
    [Abstract] [Full Text] [Related]

  • 17. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
    Tsutsumi H, Kumakawa T, Hirai M, Kikukawa M, Arie Y, Mori M, Kodo H, Nakamura N, Murai Y, Mizutani R.
    Nihon Ronen Igakkai Zasshi; 1995 Mar 01; 32(3):190-4. PubMed ID: 7596061
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA, Beardsley GP, Krikorian JG, Mortara RW, Agarwal RP.
    Cancer Res; 1983 Nov 01; 43(11):5190-3. PubMed ID: 6616454
    [Abstract] [Full Text] [Related]

  • 19. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
    Tatsumi N, Yamada K, Ohshima T, Nakamura T, Ohno R, Masaoka T, Kimura I, Kimura K.
    Gan To Kagaku Ryoho; 1990 Dec 01; 17(12):2387-95. PubMed ID: 2260876
    [Abstract] [Full Text] [Related]

  • 20. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells.
    Myers-Robfogel MW, Spataro AC.
    Cancer Res; 1980 Jun 01; 40(6):1940-3. PubMed ID: 7371029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.